Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084329 | 0.99 | CNR1 (0.60) | CNR1SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL6083987 | 0.99 | CNR1 (0.60) | CNR1SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL6083620 | 0.87 | RAB9A (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL6083629 | 0.87 | RAB9A (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL21490057 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL19701371 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL6085524 | 0.87 | RAB9A (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL6084495 | 0.86 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL6085889 | 0.86 | GRM5 (0.52) | CNR1SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL6083442 | 0.85 | ALDH1A1 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003500480-A | — | — | 2003-01-07 | — | — | JP | claimed |
| CN-1361768-A | Metabotropic glutamate receptor antagonists and their use for treating central nervous system disorders | NPS PHARMA INC (US) | 2002-07-31 | — | — | CN | claimed |
| EP-1196397-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2002-04-17 | — | — | EP | claimed |
| WO-2000073283-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| CN-1789246-A | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMA INC (US) | 2006-06-21 | — | — | CN | disclosed |
| EP-1595871-A2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2005-11-16 | — | — | EP | disclosed |
| CN-1361768-A | Metabotropic glutamate receptor antagonists and their use for treating central nervous system disorders | NPS PHARMA INC (US) | 2002-07-31 | — | — | CN | disclosed |
| EP-1196397-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2000073283-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2000-12-07 | — | — | WO | disclosed |